摘要
乳腺癌仍然是美国妇女癌症死亡的第二大原因。寻求新的可行治疗手段十分必要。本文研究了治疗三阴性乳腺癌时,使多西他奇(DTX)恒定、持续给药的纳米传递系统的优化(nDS)。DTX是高度疏水性药物,难以通过植入给药系统使其在水溶液中达到有效治疗浓度时释放。为了解决这个难题以及测试优化后多西他奇给药的恒定和持续性。我们准备了不同摩尔比的多西他奇/2-羟丙基-β-环糊精(DTX/HPCD) 包合物。 1:10 的DTX/HPCD 包合物DTX的溶解度是1:2时的5倍,游离DTX体外释放时的3倍。在SCID/Beige鼠中,与注射DTX标准药物相比,DTX/HPCD 包合物通过纳米通道系统释放时能抑制肿瘤的生长,这表明在复合物中通过纳米通道系统扩散后,DTX依然保留有结构稳定性和生物活性。
关键词: 环糊精,多西他奇,药物传递,包合物,纳米植入,持续释放。
图形摘要
Current Drug Targets
Title:Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System
Volume: 16 Issue: 14
Author(s): Silvia Ferrati, Eugenia Nicolov, Shyam Bansal, Sharath Hosali, Melissa Landis and Alessandro Grattoni
Affiliation:
关键词: 环糊精,多西他奇,药物传递,包合物,纳米植入,持续释放。
摘要: Breast cancer remains the second leading cause of cancer deaths for women in the U.S. The need for new and alternative strategies to treat this cancer is imperative. Here we show the optimization of our nanochannel delivery system (nDS) for constant and sustained delivery of docetaxel (DTX) for thetreatment of triple negative breast cancer. DTX is a highly hydrophobic drug, making it difficult to reach the therapeutic levels when released in aqueous solutions from our implantable delivery system. To overcome this challenge and test the release of DTX from nDS, we prepared DTX/2-hydroxypropyl β-cyclodextrin (DTX/HPCD) inclusion complexes in different molar ratios. The 1:10 DTX/HPCD complex achieved 5 times higher solubility than the 1:2 complex and 3 times higher in vitro release of DTX than with free DTX. When released in SCID/Beige mice from nanochannel system, the DTX/HPCD complex showed reduced tumor growth, comparable to the standard bolus injections of DTX, indicating that the structural stability and biological activity of DTX were retained in the complex, after its diffusion through the nanochannel system.
Export Options
About this article
Cite this article as:
Silvia Ferrati, Eugenia Nicolov, Shyam Bansal, Sharath Hosali, Melissa Landis and Alessandro Grattoni , Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System, Current Drug Targets 2015; 16 (14) . https://dx.doi.org/10.2174/138945011614151119125541
DOI https://dx.doi.org/10.2174/138945011614151119125541 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Protein Regulators of Eicosanoid Synthesis: Role in Inflammation
Current Protein & Peptide Science Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Exploring the Bio-efficacies of Methanolic Extracts of Nostoc muscorum and Calothrix brevissima with their Characterization Using GC-MS
The Natural Products Journal Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets Measles Virus as An Oncolytic Vector Platform
Current Gene Therapy Diversity of Anticancer and Antimicrobial Compounds from Lichens and Lichen-derived Fungi: A Systematic Review (1985-2017)
Current Organic Chemistry FDA-approved Drugs Selected Using Virtual Screening Bind Specifically to G-quadruplex DNA
Current Pharmaceutical Design Intraoperative Localisation of Impalpable Breast Lesions Utilising the ROLLIS Technique Following Peritumoral <sup>99m</sup>Tc-colloid Sentinel Node Lymphoscintigraphy
Current Radiopharmaceuticals Bilirubin and the Genome: The Hereditary Basis of Unconjugated Neonatal Hyperbilirubinemia
Current Pharmacogenomics The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders
Mini-Reviews in Medicinal Chemistry Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Zebrafish: Predictive Model for Targeted Cancer Therapeutics from Nature
Current Cancer Drug Targets A Novel Strategy for Preparing Glycopeptide Molecular Probe Using Fluorous Technology
Protein & Peptide Letters Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design